Mosaic (MOS) Bets On Enzymes While Its Core Business Bleeds
Mosaic Biosciences, a unit of The Mosaic Company (MOS), launched Renuvis Enzara, an enzyme-based treatment for crop residue. MOS reported a Q2 net loss of $273M, reversing from a $411M profit in 2025. The company cut its 2026 capex outlook to $1.2B and sold a potash mine. Phosphate segment losses widened, while Potash remained stable. Shares trade at a forward P/E of 15.92.

.jpg&w=384&q=75)

